Issue link: https://htpgraphics.uberflip.com/i/116750
Commercialising the Inhibitor SCENARIOS MISCELLANEOUS Cover here, which law governs the contract; how changes can be made; whether the contract is assignable. SIGNATURES Make sure it is signed by people AUTHORISED to sign and bind each party. During negotiations, IPP has suggested that, due to Prof. Table's input, it also has rights in the treatment. If this is correct, it may mean that Lakeland would need a licence from IPP if it wished to use the IP. Working on the basis that Lakeland does require a licence from IPP, what issues will Lakeland need to consider in negotiating the terms of the licence back? You may wish to consider the fact that Lakeland is keen to use the research and development of the treatment for non-commercial purposes (e.g. in teaching materials) rather than just in relation to research on breast cancer treatment. Brian Hodgson continues to research in the area of aromatose inhibitors after the licence has been signed with IPP and has created new improvements. He has written a detailed paper about his work which he wants to submit to a scientific journal. What should Brian be thinking about in relation to: n IP protection n the n his relationship with IPP approach to a publisher, bearing in mind his relative inexperience. A look back at the Academic Materials and Publishing Guide may help you here. 32